Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

610
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
610
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

24
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
24
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

750
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subgroups: Insights From a Single-Center Cohort.

The Journal of rheumatology·2026
Same author

Prognostic significance of 1-year pulmonary function changes in inflammatory myopathy-related interstitial lung disease.

Seminars in arthritis and rheumatism·2026
Same author

Fitbit as an activity monitor in idiopathic inflammatory myopathy: results from a real-world cohort.

Clinical and experimental rheumatology·2026
Same author

Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis.

Clinical and experimental rheumatology·2026
Same author

Detection of dermatomyositis skin rashes in skin of color: Addressing critical training gaps.

The American journal of medicine·2026
Same author

Erratum to "Magnetic resonance imaging for adult idiopathic inflammatory myopathies: a scoping review of protocols, grading systems and applications"[Seminars in Arthritis and Rheumatism Volume 75, (2025) 152865].

Seminars in arthritis and rheumatism·2026

Related Experiment Video

Updated: Sep 7, 2025

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.9K

Current and new targets for treating myositis.

Siamak Moghadam-Kia1, Chester V Oddis2

  • 1Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.

Current Opinion in Pharmacology
|June 20, 2022
PubMed
Summary

Treating refractory idiopathic inflammatory myopathies (IIM) is challenging. While rituximab and anti-IL6 therapies have shown limited success, immune globulin intravenous (IVIg) is now approved for adult dermatomyositis.

More Related Videos

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.3K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K

Related Experiment Videos

Last Updated: Sep 7, 2025

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.9K
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.3K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K

Area of Science:

  • Rheumatology and Immunology
  • Clinical Therapeutics
  • Translational Medicine

Background:

  • Idiopathic inflammatory myopathies (IIM) present treatment challenges, necessitating novel therapeutic strategies.
  • Existing therapies like rituximab have not met primary endpoints in large trials.
  • Understanding IIM pathogenesis is crucial for developing targeted treatments.

Purpose of the Study:

  • To review current and emerging therapies for refractory idiopathic inflammatory myopathies (IIM).
  • To evaluate the efficacy and limitations of various treatment modalities.
  • To highlight future directions in IIM therapeutic development.

Main Methods:

  • Review of clinical trial data for IIM treatments, including rituximab, IVIg, anti-TNF, and anti-IL6 agents.
  • Analysis of recent reports and small-case series on novel agents like abatacept, sifalimumab, JAK inhibitors, apremilast, and KZR-616.
  • Discussion of the role of biomarkers and improved classification in IIM research.

Main Results:

  • Rituximab failed to meet its primary outcome in a large IIM trial, despite some patient improvement.
  • Octagam 10% immune globulin intravenous (IVIg) received FDA approval for adult dermatomyositis.
  • Anti-TNF therapy is not recommended and may induce myositis; tocilizumab (anti-IL6) also failed to meet its primary endpoint.

Conclusions:

  • Current treatment options for refractory IIM are limited, with mixed results from established and novel therapies.
  • Emerging therapies targeting specific pathways show promise and warrant further investigation.
  • Future IIM treatment advancements depend on biomarker discovery, refined classification, and robust clinical trials.